Zhao Zihao, Zheng Wenjing, Zhang Lingling, Song Wenjie, Wang Tao
Department of Hepatobiliary Surgery, Affiliated Xijing Hospital, Air Force Medical University, Xi'an 710032, China.
Department of Medical Genetics and Developmental Biology, Basic Medical Science Academy, Air Force Medical University, Xi'an 710032, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2025 Apr;41(4):308-317.
Objective To investigate the clinical relevance and diagnostic or prognostic value of ST3β-galactoside α-2, 3-sialyltransferase 1 (ST3GAL1) in glioma and to confirm its role in promoting malignant phenotypes. Methods Using data from The Cancer Genome Atlas (TCGA) database, we analyzed the correlation between ST3GAL1 expression levels in glioma and clinical parameters to evaluate its diagnostic and prognostic value. The impact of ST3GAL1 on malignant phenotypes of glioma cells-including proliferation, cell cycle progression, apoptosis, and invasion was further validated through ST3GAL1 knockdown experiments. Results The expression level of ST3GAL1 was significantly higher in glioma tissues compared to healthy brain tissues and showed a strong correlation with clinical characteristics of glioma patients. Survival analysis and receiver operating characteristic (ROC) curve demonstrated that ST3GAL1 could serve as a potential diagnostic and prognostic biomarker for glioma. Knockdown of ST3GAL1 suppressed proliferation, invasion, and migration capabilities of glioma cell lines, and induced G1-phase cell cycle arrest. Conclusion ST3GAL1 promotes malignant phenotypes in glioma and plays a critical role in its malignant progression, suggesting its potential as a biomarker for glioma diagnosis and prognosis.
目的 探讨ST3β-半乳糖苷α-2,3-唾液酸转移酶1（ST3GAL1）在胶质瘤中的临床相关性及诊断或预后价值，并证实其在促进恶性表型中的作用。方法 利用癌症基因组图谱（TCGA）数据库的数据，分析胶质瘤中ST3GAL1表达水平与临床参数之间的相关性，以评估其诊断和预后价值。通过ST3GAL1敲低实验进一步验证ST3GAL1对胶质瘤细胞恶性表型的影响，包括增殖、细胞周期进程、凋亡和侵袭。结果 与健康脑组织相比，胶质瘤组织中ST3GAL1的表达水平显著更高，且与胶质瘤患者的临床特征密切相关。生存分析和受试者工作特征（ROC）曲线表明，ST3GAL1可作为胶质瘤潜在的诊断和预后生物标志物。敲低ST3GAL1可抑制胶质瘤细胞系的增殖、侵袭和迁移能力，并诱导G1期细胞周期停滞。结论 ST3GAL1促进胶质瘤的恶性表型，在其恶性进展中起关键作用，提示其作为胶质瘤诊断和预后生物标志物的潜力。
